{"id":"W1592261436","doi":"10.1186/ar1407","title":"An open-label safety and efficacy study of an anti-CD20 antibody (rituximab, Rituxan) for anti-B-cell therapy in the treatment of systemic lupus erythematosus","year":2004,"lang":"en","type":"article","venue":"Arthritis Research","topic":"Monoclonal and Polyclonal Antibodies Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"Canadian Arthritis Network; School of Medicine, University of California, San Diego; Menzies Institute for Medical Research; National Cancer Institute; Arthritis Society; University of North Carolina at Chapel Hill; Genentech; National Institutes of Health; Biogen; Lupus Research Institute; Pfizer; Natural Sciences and Engineering Research Council of Canada; Dutch Arthritis Association; Oesterreichische Nationalbank; Deutsche Forschungsgemeinschaft; Nuffield Foundation; Physiotherapy Foundation of Canada; Canadian Institutes of Health Research; National Institute of Arthritis and Musculoskeletal and Skin Diseases; Lupus Research Alliance; Wellcome Trust; Newcastle University; National Institute of Allergy and Infectious Diseases; Howard Hughes Medical Institute; Austrian Science Fund; Arthritis Foundation","keywords":"Business","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.01042495,0.001521461,0.004144397,0.001063938,0.0008181838,0.001420777,0.001636805,0.002524982,0.006233876],"category_scores_gemma":[0.006709702,0.0006409318,0.002316382,0.0007031169,0.00246766,0.001894132,0.0007918624,0.003248461,0.001318773],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001603635,"about_ca_system_score_gemma":0.001836913,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007157752,"about_ca_topic_score_gemma":0.001067684,"domain_scores_codex":[0.992785,0.004603925,0.0004448958,0.0008107608,0.0009656188,0.0003898946],"domain_scores_gemma":[0.9921845,0.002991532,0.00182688,0.0008259722,0.0006916915,0.00147939],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.8889074,0.05619434,0.002481457,0.001205649,0.001084808,0.0001246295,0.0002771597,0.0002893505,0.002644077,0.000147443,0.0005721889,0.04607152],"study_design_scores_gemma":[0.3664637,0.6227787,0.007533103,0.00008711687,0.0005889948,0.00007342142,0.00005050894,0.0002997673,0.0005755589,0.0001043381,0.001418548,0.00002626151],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9742641,0.009105003,0.001186737,0.0003993682,0.000634638,0.01078643,0.0009446515,0.00009011551,0.00258889],"genre_scores_gemma":[0.9822581,0.002897642,0.001674235,0.0007221097,0.001243939,0.008080449,0.0007756999,0.0000163758,0.002331477],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01042495,"threshold_uncertainty_score":0.05513304,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.09168574659915207,"score_gpt":0.4325235346135642,"score_spread":0.3408377880144122,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}